Literature DB >> 30612343

Optimal management of major bleeding on DOACs: not only reversal agents.

Silvia Galliazzo1, Alessandro Squizzato2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30612343     DOI: 10.1007/s11739-018-02020-0

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  9 in total

1.  Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTH.

Authors:  N Khorsand; A Majeed; R Sarode; J Beyer-Westendorf; S Schulman; K Meijer
Journal:  J Thromb Haemost       Date:  2015-10-27       Impact factor: 5.824

2.  Italian intersociety consensus on DOAC use in internal medicine.

Authors:  Domenico Prisco; Walter Ageno; Cecilia Becattini; Armando D'Angelo; Giovanni Davì; Raimondo De Cristofaro; Francesco Dentali; Giovanni Di Minno; Anna Falanga; Gualberto Gussoni; Luca Masotti; Gualtiero Palareti; Pasquale Pignatelli; Roberto M Santi; Francesca Santilli; Mauro Silingardi; Antonella Tufano; Francesco Violi
Journal:  Intern Emerg Med       Date:  2017-02-13       Impact factor: 3.397

3.  Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry.

Authors:  Sophie Testa; Walter Ageno; Emilia Antonucci; Rossella Morandini; Jan Beyer-Westendorf; Maurizio Paciaroni; Marc Righini; Piera Sivera; Peter Verhamme; Vittorio Pengo; Daniela Poli; Gualtiero Palareti
Journal:  Intern Emerg Med       Date:  2018-05-22       Impact factor: 3.397

4.  Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate.

Authors:  Marwan Sheikh-Taha
Journal:  Intern Emerg Med       Date:  2018-11-09       Impact factor: 3.397

5.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.

Authors:  S Schulman; C Kearon
Journal:  J Thromb Haemost       Date:  2005-04       Impact factor: 5.824

6.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.

Authors:  Christian T Ruff; Robert P Giugliano; Eugene Braunwald; Elaine B Hoffman; Naveen Deenadayalu; Michael D Ezekowitz; A John Camm; Jeffrey I Weitz; Basil S Lewis; Alexander Parkhomenko; Takeshi Yamashita; Elliott M Antman
Journal:  Lancet       Date:  2013-12-04       Impact factor: 79.321

7.  The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2.

Authors:  Menno V Huisman; Kenneth J Rothman; Miney Paquette; Christine Teutsch; Hans-Christoph Diener; Sergio J Dubner; Jonathan L Halperin; Chang Sheng Ma; Kristina Zint; Amelie Elsaesser; Dorothee B Bartels; Gregory Y H Lip
Journal:  J Am Coll Cardiol       Date:  2017-02-21       Impact factor: 24.094

8.  Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

Authors:  Stuart J Connolly; Truman J Milling; John W Eikelboom; C Michael Gibson; John T Curnutte; Alex Gold; Michele D Bronson; Genmin Lu; Pamela B Conley; Peter Verhamme; Jeannot Schmidt; Saskia Middeldorp; Alexander T Cohen; Jan Beyer-Westendorf; Pierre Albaladejo; Jose Lopez-Sendon; Shelly Goodman; Janet Leeds; Brian L Wiens; Deborah M Siegal; Elena Zotova; Brandi Meeks; Juliet Nakamya; W Ting Lim; Mark Crowther
Journal:  N Engl J Med       Date:  2016-08-30       Impact factor: 91.245

Review 9.  Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.

Authors:  Nick van Es; Michiel Coppens; Sam Schulman; Saskia Middeldorp; Harry R Büller
Journal:  Blood       Date:  2014-06-24       Impact factor: 22.113

  9 in total
  1 in total

Review 1.  Reversal agents for oral anticoagulant-associated major or life-threatening bleeding.

Authors:  Marco Moia; Alessandro Squizzato
Journal:  Intern Emerg Med       Date:  2019-08-24       Impact factor: 3.397

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.